e-Therapeutics Stock Price, News & Analysis (LON:ETX)

GBX 10.25 0.30 (3.02 %)
(As of 01/18/2018 09:08 AM ET)
Previous CloseGBX 9.95
Today's RangeGBX 9.50 - GBX 10.25
52-Week RangeGBX 6 - GBX 13.12
Volume35,189 shs
Average Volume100,549 shs
Market Capitalization£22.17 million
P/E Ratio-341.67
Dividend YieldN/A
BetaN/A

About e-Therapeutics (LON:ETX)

e-Therapeutics plc is a United Kingdom-based drug discovery and development company. The Company's discovery platform is based on the network of pharmacology and chemical biology. The Company operates in the business segment of drug discovery and development. The Company applies its platform to the discovery of new drug candidates. The therapeutic focus of the Company's discovery activity is in immuno-oncology, addressing drug resistance in targeted cancer therapies and antivirals. The Company generates a range of preclinical stage assets, including ETX1153c, a functionally resistance-less antibiotic; ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule antiTNFα; ETS2400, in Hedgehog pathway inhibition, and ETS5200, which delivers a range of spectrum antivirals. The Company has completed a Phase IIb study of a drug candidate for depressive disorder, ETS6103, as well as Phase I clinical trials in cancer for ETS2101.

Receive ETX News and Ratings via Email

Sign-up to receive the latest news and ratings for ETX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolLON:ETX
CUSIPN/A
Phone+44-1993-880000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-341.666666666667
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSGBX (0.03)
Net IncomeN/A
Net MarginsN/A
Return on Equity-40.76%
Return on Assets-37.10%

Miscellaneous

EmployeesN/A
Outstanding Shares268,470,000

e-Therapeutics (LON:ETX) Frequently Asked Questions

What is e-Therapeutics' stock symbol?

e-Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "ETX."

Who are some of e-Therapeutics' key competitors?

Who are e-Therapeutics' key executives?

e-Therapeutics' management team includes the folowing people:

  • Iain Gladstone Ross, Executive Chairman of the Board (Age 62)
  • Raymond John Barlow, Chief Executive Officer, Director (Age 48)
  • Steven Medlicott, Chief Financial Officer, Interim Chief Operating Officer, Director (Age 50)
  • Trevor M. Jones Ph.D., CBE, Non-Executive Director (Age 74)
  • Christine Helen Soden, Non-Executive Director

How do I buy e-Therapeutics stock?

Shares of e-Therapeutics and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is e-Therapeutics' stock price today?

One share of e-Therapeutics stock can currently be purchased for approximately GBX 10.25.

How big of a company is e-Therapeutics?

e-Therapeutics has a market capitalization of £22.17 million.

How can I contact e-Therapeutics?

e-Therapeutics' mailing address is 17 Blenheim Office Park, WITNEY, OX29 8LN, United Kingdom. The company can be reached via phone at +44-1993-880000.


MarketBeat Community Rating for e-Therapeutics (ETX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  65 (Vote Outperform)
Underperform Votes:  76 (Vote Underperform)
Total Votes:  141
MarketBeat's community ratings are surveys of what our community members think about e-Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

e-Therapeutics (LON:ETX) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Earnings History for e-Therapeutics (LON:ETX)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

e-Therapeutics (LON:ETX) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for e-Therapeutics (LON:ETX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

e-Therapeutics (LON ETX) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for e-Therapeutics (LON:ETX)

e-Therapeutics (LON ETX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/2/2018Trevor Mervyn JonesInsiderBuy59,460GBX 9£5,351.40
12/15/2017Steve MedlicottInsiderBuy200,000GBX 9£18,000
8/22/2017Iain Gladstone RossInsiderBuy250,000GBX 11£27,500
7/3/2017Trevor Mervyn JonesInsiderBuy45,364GBX 1,213£550,265.32
6/1/2017Steve MedlicottInsiderBuy1,000,000GBX 6£60,000
5/12/2017Trevor Mervyn JonesInsiderBuy59,400GBX 8£4,752
1/3/2017Trevor Mervyn JonesInsiderBuy36,917GBX 7£2,584.19
1/21/2015Steve MedlicottInsiderBuy150,000GBX 25.25£37,875
(Data available from 1/1/2013 forward)

Headlines

e-Therapeutics (LON ETX) News Headlines

Source:
DateHeadline
Edison Issues Update on e-Therapeutics (ETX)Edison Issues Update on e-Therapeutics (ETX)
finance.yahoo.com - January 5 at 9:07 AM
What’s Installed For e-Therapeutics plc (LON:ETX)?What’s Installed For e-Therapeutics plc (LON:ETX)?
finance.yahoo.com - January 3 at 5:49 PM
Trevor Mervyn Jones Acquires 59,460 Shares of e-Therapeutics plc (ETX) StockTrevor Mervyn Jones Acquires 59,460 Shares of e-Therapeutics plc (ETX) Stock
www.americanbankingnews.com - January 3 at 9:34 AM
e-Therapeutics plc (ETX) Insider Steve Medlicott Purchases 200,000 Sharese-Therapeutics plc (ETX) Insider Steve Medlicott Purchases 200,000 Shares
www.americanbankingnews.com - December 18 at 8:36 AM
Is It The Right Time To Buy e-Therapeutics plc (AIM:ETX)?Is It The Right Time To Buy e-Therapeutics plc (AIM:ETX)?
finance.yahoo.com - November 3 at 12:44 PM
Have Investors Already Priced In e-Therapeutics plc’s (AIM:ETX) Growth?Have Investors Already Priced In e-Therapeutics plc’s (AIM:ETX) Growth?
finance.yahoo.com - September 15 at 7:00 PM
e-Therapeutics plc (ETX) to Release Quarterly Earnings on Mondaye-Therapeutics plc (ETX) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - September 11 at 1:46 AM
Insider Buying: e-Therapeutics plc (ETX) Insider Acquires 250,000 Shares of StockInsider Buying: e-Therapeutics plc (ETX) Insider Acquires 250,000 Shares of Stock
www.americanbankingnews.com - August 22 at 1:14 PM
e-Therapeutics Announces Outcome of Strategic Review and Future Planse-Therapeutics Announces Outcome of Strategic Review and Future Plans
finance.yahoo.com - July 24 at 9:56 AM
Insider Buying: e-Therapeutics plc (ETX) Insider Buys 45,364 Shares of StockInsider Buying: e-Therapeutics plc (ETX) Insider Buys 45,364 Shares of Stock
www.americanbankingnews.com - July 4 at 1:40 PM
Appointment of Paul Stockdale as CFO - London South East (registration) (blog)Appointment of Paul Stockdale as CFO - London South East (registration) (blog)
www.lse.co.uk - July 1 at 6:02 PM
E-Therapeutics depression drug trials miss targetsE-Therapeutics depression drug trials miss targets
uk.finance.yahoo.com - February 15 at 5:16 AM
BUZZ-E-therapeutics: biggest one-day drop as antidepressant study disappointsBUZZ-E-therapeutics: biggest one-day drop as antidepressant study disappoints
uk.finance.yahoo.com - February 15 at 4:32 AM
e-Therapeutics plc Announces Full Year Resultse-Therapeutics plc Announces Full Year Results
uk.finance.yahoo.com - March 31 at 2:14 AM

SEC Filings

e-Therapeutics (LON:ETX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

e-Therapeutics (LON ETX) Stock Chart for Thursday, January, 18, 2018

Loading chart…

This page was last updated on 1/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.